Decimate Dengue : The Pre-Summit Webinars: DECIMATE DENGUE: HEALTH ECONOMICS AND PUBLIC-PRIVATE PARTNERSHIPS (8th Webinar)

 

00:00 “Introduction” by Prof. Zulkifli Ismail, Chairperson
04:45 “Economics of Prevention and Control of Dengue” by Prof. Dato’ Dr. Syed Mohamed Aljunid
22:08 “Fighting Dengue with Inclusive Insurance Products” by Mr. Goh Theng Kiat
44:51 “Q&A”
01:29:43 Closing Remarks


Decimate Dengue : The Pre-Summit Webinars: PREDICTORS OF SEVERE DENGUE – WHAT’S NEW? (6th Webinar)

00:00:00 Introduction by Prof Usa Thisyakorn
00:03:44 A CURIOUS CASE OF DENGUE by Assoc Prof Somia Iqtadar, King Edward Medical University Lahore, Pakistan
00:23:27 CORTISOL: A NEW PREDICATOR OF SEVERE DENGUE by Assistant Professor Dr Chansuda Bongsebandhu-phubhakdi, Department of Paediatrics, Faculty of Medicine, Chulalongkorn University, Thailand
00:40:30 THE ROLE OF CIRCULATING MICRONRNAS (miRNAS) AS BIOMARKERS FOR PREDICTING SEVERE DENGUE by Assoc Prof Nattachai Srisawat, Tropical Medicine Cluster, Chulalongkorn University, Thailand
*****
Q&A Session
00:59:12 “Which one is superior – dextran or gelafundin – in shock for dengue? Which do you prefer?”
01:03:28 “Are there any strong correlations of microRNA in the pathogenesis of dengue infection, and are these microRNA specific ony for dengue infections?”
01:04:14 “What’s next for predictors of severe dengue?”
01:07:15 “Prof Iqtadar, do you have anything to say about corticosteroids in your management of dengue patients?”
01:10:33 “Prof Lulu, after hearing all these presentations, what do you think is next?”
01:13:19 “Dr Somia, should we aspirate and drain the concealed hemorrhage?”
01:15:10 “Dr Somia, why does the pleural effusion need to be aspirated?”
01:17:23 “Dr Chansuda, there are publications which talk about cortisol levels in severe dengue vs non-severe dengue. Some have reported that in severe dengue there’s actually lower cortisol levels than non-severe dengue. How do you reconcile some of these different observations? Is it a matter of timing or stage of the disease?”
01:19:18 “Prof Nattachai, I was just reading an article from Singapore looking at the microRNA from dengue. There are many papers that talk about different expressions, different microRNA in different studies. Do you think we could in the next phase or ultimately come up with a panel of selected microRNAs? Or do you think these will be location-specific or individual-specific? Is there going to be a generalisable selection of microRNAs that we can actually apply in the assessment of dengue disease or any other disease?”
01:21:46 “Are there any clinical signs that will guide clinicians on when to get cortisol levels and how often do we monitor?”
01:23:09 “Prof Somia, how do you think (clinical signs for cortisol levels) could be applied in clinical practice?”


Decimate Dengue: 5th Webinar PRE-VACCINATION SCREENING – WHAT’S NEXT (15 November 2021)

2:08 UPDATE ON DENGUE SEROPREVALENCE AND RAPID DIAGNOSTIC TESTS by Prof. Sutee Yoksan, Emeritus Professor of Pathobiology, Consultant of Centre for Vaccine Development, Institute of Molecular Biosciences, Mahidol University and Chulabhorn Research Institute, Thailand
24:03 STRATEGIES FOR DENGUE PRE-VACCINATION SCREENING by Prof. Usa Thisyakorn Executive Director, Tropical Medicine Cluster, Chulalongkorn University, Bangkok, Thailand
Q&A Session
47:40 Why is dengue vaccination given to children 9 to 14 years old? Why is there a need to check seropositivity before giving the vaccine?
54:10 In the absence of PRNT, what ELISA (test) should be used for pre-vaccination screening? Dengue IgG capture ELISA or IgG indirect ELISA? Any brand comparison of the ELISA tests?
56:25 From the data given, the rapid dengue test is not as good as the gold standard and looks like it is not performing as well. But pre-vaccination requires rapid diagnostic tests. What are your thoughts on this?
1:02:40 Any possibility of having other potential tests (reference tests from all countries) replacing PRNT for pre-vaccination screening?
1:04:34 If countries with high sero-prevalence of more than 80% can waive pre-screening for dengue before vaccination, what countries can do this?
1:08:44 Would the Takeda vaccine need pre-vaccination screening as well?
1:10:37 Dengvaxia is licensed in Thailand. Is it given by paediatricians or family physicians in your country?
1:14:28 Cross reactivity: will the sensitivity or specificity of rapid or ELISA tests for previous dengue exposure vary based on other non-dengue circulating flaviviruses? Will the non-PRNT tests need to be validated on populations with different flavivirus exposure backgrounds?
1:17:09 If someone has confirmed dengue in the past, would he still need to be screened before vaccination?
1:21:35 Can you comment on the use of DBS (Direct Blood Smear or Dried Blood Spots) in dengue antibody tests?


Decimate Dengue: 4th Webinar STRATEGIES FOR VECTOR CONTROL – THE WOLBACHIA STORY (15 September 2021)

0:00 Kickoff of 4th Webinar ‘STRATEGIES FOR VECTOR CONTROL – THE WOLBACHIA STORY’ by Prof Zulkifli Ismail

2:41 Introduction of 1st speaker, Ms Sakunthala Janaki, by Prof. Hadinegoro

4:49 ‘Pilot Implementation of Wolbachia Project in Colombo district, Sri Lanka: Entomological aspects’ by Ms Sakunthala Janaki, Entomologist, National Dengue Control Unit, Ministry of Health Sri Lanka

29:30 Introduction of 2nd speaker, Dr Norhayati Mokhtar, by Prof. Ismail

30:39 ‘Strategies for Vector Control Using Wolbachia: An Operationalization in Malaysia’ by Dr Norhayati Mokhtar, Public Health Specialist, Senior Principal Assistant Director (Dengue), Vector Borne Disease Sector, Disease Control Division, Ministry of Health Malaysia

57:14 Introduction of 3rd speaker, Dr Claudia Surjadjaja, by Prof Hadinegoro

59:26 ‘Mosquito Story: From Indonesia to the World’ by Dr Claudia Surjadjaja, Regional Director Asia, World Mosquito Program (WMP) Question and Answer Session:

1:15:30 “How does WMP choose the countries that it works with?”

1:16:35 “I could see the decreased cases with the projects in all the countries, but I wonder how is the vector density with the virus?”

1:18:04 “Can the Wolbachia mosquito initiative be combined with Oxytec genetically modified mosquito technology to further strengthen our fight against mosquito-borne diseases?”

1:19:25 “What has the program cost been so far, where has the funding come from, and what is the size of the human population being protected?” 1:22:25 “How long is the program from training to full implementation?”

1:23:56 For Dr. Norhayati: “How do you explain the dengue trend – so low in 2021 vs. the past 5 years?”

1:27:35 For Dr. Norhayati: “Has the government of Malaysia already accepted this (Wolbachia) program and will it apply (the program) all over Malaysia?”

1:28:29 For Dr. Claudia: “How do you handle the Wolbachia operations since most of the areas are restricted to movement due to COVID-19? How do you actually go about your work when there is restriction of movement of people and research team?”

1:30:30 For Dr. Claudia: “In the study site for trap deployment, why did they use grid sizes of 333 meters? Is there any significance to this 333?

1:31:18 For Dr. Norhayati: “During this COVID-19 pandemic, is there any possibility that people with mild symptoms of dengue will refrain from visiting health centers?”

1:31:41 For Dr. Norhayati: “Presenting the change in dengue cases pre- and post-release in the form of case proportion over the total number of cases in region or district or area, for example in the form of dengue case ratio, be a more accurate picture of the positive effect of the program? This is because dengue incidence in an area changes with time.”

1:34:35 For Dr. Norhayati: “What is the size of the population in the 30 localities and what are the indicators of public support for the program?”

1:36:45 “Are there any studies where they compare Wolbachia-infected mosquitoes and non-Wolbachia-infected mosquitoes?”

1:37:43 “What do you think will be the role of the Wolbachia program in the bigger picture of dengue control?”

1:38:52 “Can Wolbachia methodology be implemented together with other vector control activities?”

1:39:25 For Dr. Claudia: “Will the WMP be brought to the Philippines? What other countries will WMP be brought to?”

1:40:16 “Are there any challenges in communicating with the communities, especially in the study sites?”

24th March 2021:
Impact of the COVID-19 Pandemic on the Global Dengue Situation

00:00 “Introduction” by Prof. Zulkifli Ismail, Chairperson

07:06 “COVID-19 and DENGUE in SINGAPORE” by Prof. Ng Lee Ching

29:12 “Dengue transmission during COVID-19 lockdown: the influence of human mobility in Sri Lanka” by Dr. Hasitha Tissera

54:02 “Closing Remarks” by Prof. Zulkifli Ismail & Panelists

20th January 2021:
Managing the Severely Ill Dengue Patient – Adults & Children

20th January 2021:
Q&A Discussion: Managing the Severely Ill Dengue Patient – Adults & Children

00:08​ – “What’s the role of platelets transfusion in severe adult dengue with thrombocytopenia and what is the cutoff point of platelets to transfuse? Is there any role of steroids in managing myocarditis in dealing with dengue in adult patients?”

02:10​ – “What is the role of CVP in assisting with fluid management for dengue shock syndrome (DSS) in children? What is the role of ECHO in looking at IVC collapsibility in assisting fluid replacement in DSS children?”

05:20​ – “In severe liver involvement in children, is there any role of IV NAC, like in adults?”

08:36​ – Closing Remarks by Prof Zulkifli Ismail

28th October 2020:
Randomised Trials of Wolbachia for Dengue Control – A Step Towards Elimination?

28th October 2020:
Q&A Discussion: Randomised Trials of Wolbachia for Dengue Control – A Step Towards Elimination? 

00:00 – Introduction to Panelists by Chairperson Prof. Ooi Eng Eong –
00:50 – Panelists’ first impression of Prof. Simmons’ findings –
04:18 Prof. Ooi: “What were the responses from the residents, local government and health officials of Yogyakarta, and what’s next?”
05:45 Prof. Ooi: “What are some of your impressions and how do you see the impact on ASEAN and other parts of the world?”
08:27 – A multi-part question from Prof. Ng Lee Ching, Environmental Health Insitutute, Singapore … –
11:39 Webinar participant: “What were the differences between the release strategy in Indonesia vis-a-vis in Vietnam that made the Indonesia release more successful?”
12:49 Webinar participant: “How did you convince local authorities and residents of Yogyakarta to get on board with the release of more mosquitoes into their environment?”
16:55 Webinar participant: “Was there a dengue outbreak in the city during the period when the trial was conducted?”
18:53 Webinar participant: “What is the future of arbovirus control? Should public health programs focus on one method or a set of them?”
23:06 Webinar participant: “Did you continue to educate residents on source reduction or allow residents to adopt less vigilant approach knowing that the Wolbachia mosquito will do the job? Are residents and premises owners like construction sites fined when mosquito breeding is detected in their premises?” 25:12 Webinar participant: “Did the dengue vaccine controversy pose any challenges to the carrying out of the study?”
25:38 Webinar participant: “How do you know that the eggs will hatch? How many hatched?”
26:02 Prof. Ooi: “Is there a need for bridging studies to determine the effectiveness of this program in different parts of the world?”
27:30 Webinar participant: “What is the status of decreasing vectorial capacity of albopictus by Wolbachia superinfection or other means?”
29:27 Webinar participant: “I saw that the mosquito population index has one peak a year. In Singapore we have seen 2 peaks in a year from our gravitrap surveillance network. Do you know what drives the mosquito population up and down?”
31:37 Webinar participant: “In raising your Wolbachia infected mosquito stocks, is there an alternative to human volunteers as a blood source?”
33:11 End of Discussion – Closing Remarks